{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-006483","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.008430+00:00","generated_at":"2026-05-16T07:52:53.196597+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Milestone launches CARDAMYST nasal spray for PSVT via U.S. retail pharmacies","bullets":["CARDAMYST (etripamil) is now available through U.S. retail pharmacies as first self-administered PSVT treatment.","National sales force deployment set for mid-February 2026 to support commercialization.","Eligible commercially insured patients receive a $25 copay cap via patient assistance program.","FDA approved CARDAMYST on December 12, 2025 — first PSVT therapy approved in over 30 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-006483","json":"https://secwatch.observer/filing/0001104659-26-006483.json","markdown":"https://secwatch.observer/filing/0001104659-26-006483.md","text":"https://secwatch.observer/filing/0001104659-26-006483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926006483/0001104659-26-006483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926006483/tm263973d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:52:53.196597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}